The influence of long-term cimetidine as an adjuvant to pancreatic enzyme therapy in cystic fibrosis.
Seventeen patients on constant doses of pancreatic enzymes were randomised to receive either cimetidine or placebo for either of two successive six month periods. Nutritional state and maldigestion were assessed at the beginning and end of each period. Reductions in mean values of faecal fat, nitrogen, wet weight, and bile salts of approximately 30% were found on cimetidine therapy. Results showed considerable variation and only the fall in faecal fat was statistically significant. No benefit was demonstrated for height, weight, skinfold thickness, albumin, vitamin A, bone age or Crispin-Norman score.
D000293:Adolescent; D000328:Adult; D001647:Bile Acids and Salts / Q000378:metabolism; D002648:Child; D002675:Child, Preschool; D002927:Cimetidine / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003550:Cystic Fibrosis / Q000188:drug therapy*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005243:Feces / Q000032:analysis; D005260:Female; D006801:Humans; D050356:Lipid Metabolism; D008297:Male; D009747:Nutritional Physiological Phenomena; D010194:Pancreatin / Q000627:therapeutic use*; D014815:Vitamins / Q000378:metabolism
D001647:Bile Acids and Salts; D014815:Vitamins; D002927:Cimetidine; D010194:Pancreatin